## ABSTRACT OF THE DISCLOSURE

Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed *in vivo* or *ex vivo*. The modified peptides are administered to treat humans with diabetes and other related diseases.